Genmab's Strategic Stock Unit and Warrant Grant Update
Grant of Restricted Stock Units and Warrants by Genmab
Company Announcement
September 26, 2025 – Genmab A/S (Nasdaq: GMAB) made an important announcement regarding its employee compensation program. The Board of Directors has approved the granting of 14,353 restricted stock units and 9,681 warrants to employees within the organization and its subsidiaries.
These restricted stock units are awarded at no cost, providing employees with a conditional right to receive one share in Genmab A/S with a nominal value of DKK 1. Each unit corresponds to the fair market value of DKK 1,852.50, which reflects the closing market price on the grant date.
The vesting of the restricted stock units will occur on the first banking day of the month following three years from the grant date. The employees must also meet specific vesting conditions outlined in the restricted stock unit program established by the Board. For additional details on this program, interested parties can visit Genmab's official website under Investors > Governance > Compensation > Restricted Stock Units.
In conjunction with the restricted stock units, the warrants granted are equally attractive. Each warrant has an exercise price of DKK 1,852.50 and offers the holder the right to subscribe for one share of nominally DKK 1 upon exercising the warrant. The fair value of each warrant, calculated using the Black-Scholes formula, stands at DKK 571.09.
The warrants will become exercisable three years after the grant date and will expire on the seventh anniversary of that date. Information regarding the warrant scheme can also be found on Genmab's website under Investors > Governance > Compensation > Warrants.
About Genmab’s Vision and Commitment
About Genmab
Genmab is a premier biotechnology firm with a mission to empower its dedicated team to enhance patient lives through distinguishable antibody therapeutics. With over 25 years of experience, Genmab’s committed team has developed innovative technology platforms aimed at producing next-generation antibody medications, which include bispecific T-cell engagers, antibody-drug conjugates, and modulators for immune checkpoints. Their goal is to deliver cutting-edge (KYSO) antibody medicines that redefine cancer treatment by the year 2030.
Founded in 1999, Genmab operates out of its headquarters in Copenhagen, Denmark, and has expanded its influence across North America, Europe, and the Asia Pacific regions. More information on Genmab's initiatives can be found on their official website and social media platforms such as LinkedIn and X.
Contact Information for Genmab
For any inquiries, please reach out to:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
Frequently Asked Questions
What are restricted stock units and warrants?
Restricted stock units are a type of equity compensation that companies offer to employees, granting a right to receive shares in the future. Warrants are similar to options, allowing holders to purchase shares at a predetermined price.
How long do employees have to wait to see the benefits from these grants?
The restricted stock units will vest after three years, while the warrants will become exercisable after the same duration, expiring after seven years.
What is the significance of Genmab’s stock grant?
This grant reflects Genmab's commitment to fostering employee loyalty and aligning their interests with the company's long-term growth and success.
What are the future plans of Genmab regarding their product offerings?
Genmab is focused on developing innovative therapies aimed at treating cancer and other serious diseases with next-generation antibody medicines by 2030.
How can I find more information about Genmab's stock programs?
You can visit Genmab’s official website under the Investors section, where more detailed information about their restricted stock units and warrants is provided.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
